[journal review] 소화기내과 HCC treatment
- 최초 등록일
- 2019.03.11
- 최종 저작일
- 2018.05
- 25페이지/ 어도비 PDF
- 가격 1,000원
목차
1. Introduction
2. Objectives
3. Method
4. Result
5. Discussion
본문내용
Introduction
• Hepatocellular carcinoma (HCC): 4th leading cause of cancer worldwide
• 25-70% of HCC diagnosed at advanced stage
• Median overall survival (OS): 4.2-7.9 months due to limited treatment options
• Sorafenib: only treatment shown to extend OS for advanced HCC (Ad-HCC)
• Limitations: low response rates, modest survival advantages, high level heterogeneity of individual response, insensitivity for populations with hepatitis B virus (HBV) infection
• Recent study:
• Hepatic arterial infusion chemotherapy (HAIC) alone or accompanied with sorafenib in Ad-HCC: favorable results in response rates and survival
• Directly deliver chemotherapeutic agents into tumor associated hepatic arterial branches at increased local concentrations & greater first-pass effect in liver
→ stronger antitumor efficacy, lower systemic toxicity
• Response rates of HAIC unstable (7-81%)
• No standard and widely recognized regimen in HAIC for Ad-HCC
• FOLFOX (oxaliplatin + fluorouracil & leucovorin): effective clinical trial
참고 자료
없음